Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 5/20 | 0.39 |
| ▸ | AKT1 | P31749 | 8/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.37 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.37 |
| ▸ | RAF1 | P04049 | 1/20 | 0.37 |
| ▸ | BRAF | P15056 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.35 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.35 |
| ▸ | ATR | Q13535 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21143918 | 1.00 | MTOR (0.39) | MTORAKT1PIK3CAPIK3R1RAF1 | |
| SCHEMBL31127096 | 0.80 | MTOR (0.42) | MTORAKT1PIK3CAPIK3R1RAF1 | |
| SCHEMBL21143651 | 0.80 | MTOR (0.42) | MTORAKT1PIK3CAPIK3R1RAF1 | |
| SCHEMBL21166287 | 0.76 | AKT1 (0.43) | AKT1PIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL19687437 | 0.70 | KDM4E (0.39) | MTORPIK3CD | |
| SCHEMBL2625359 | 0.67 | PIK3CA (0.41) | MTORPIK3CAPIK3R1PIK3CDPIK3CB | |
| SCHEMBL28429340 | 0.67 | GPR119 (0.45) | MTORPIK3CA | |
| SCHEMBL21166288 | 0.63 | GPR119 (0.39) | — | |
| SCHEMBL29089141 | 0.63 | POLB (0.48) | AKT1 | |
| SCHEMBL29173113 | 0.63 | KDM1A (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317705-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2024-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317705-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | MTOR 1488/4885AKT1 3340/4885PIK3CA 1182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.